A preclinical in vivo study of CD19-directed memory-like CAR-NK cells (anti-CD19.CD8a.4-1BB.CD3ζ.CAR-PBNK) found the therapy to be safe and demonstrated increased efficacy against lymphoma compared with conventional CD19-directed CAR-NK cells. This evidence concerns the gene CD19 and lymphoma.